Physician Perceptions About Generic Drugs

Background With constrained health-care resources, there is a need to understand barriers to cost-effective medication use. Objective To study physician perceptions about generic medications. Methods Physicians used 5-point Likert scales to report perceptions about cost-related medication nonadherence, the efficacy and quality of generic medications, preferences for generic use, and the implications of dispensing medication samples. Descriptive statistics were used to assess physician perceptions and logistic regression models were used to evaluate predictors of physician perceptions. Results: Among the invited sample. 839 (30.4%) responded and 506 (18.3%) were eligible and included in the final study population. Over 23% of physicians surveyed expressed negative perceptions about efficacy of generic drugs, almost 50% reported negative perceptions about quality of generic medications, and more than one quarter do not prefer to use generics as first-line medications for themselves or for their family. Physicians over the age of 55 years were 3.3 times more likely to report negative perceptions about generic quality, 5.8 times more likely to report that they would not use generics themselves, and 7.5 times more likely to state that they would not recommend generics for family members (p < 0.05 for all). Physicians reported that pharmaceutical company representatives are the most common (75%) source of information about market entry of a generic medication. Almost half of the respondents expressed concern that free samples may adversely affect subsequent affordability, yet two thirds of respondents provide free samples. Conclusions: A meaningful proportion of physicians expressed negative perceptions about generic medications, representing a potential barrier to generic use. Payors and policymakers trying to encourage generic use may consider educational campaigns targeting older physicians.

[1]  K. Tomaszewski,et al.  Patient and physician reactions to generic antiepileptic substitution in the treatment of epilepsy , 2005, Epilepsy & Behavior.

[2]  Riyaj Shamsudeen Do Not Use , 2011 .

[3]  A. Kesselheim,et al.  Seizure Outcomes Following the Use of Generic versus Brand-Name Antiepileptic Drugs , 2010, Drugs.

[4]  L. Casalino,et al.  Patient-physician communication about out-of-pocket costs. , 2003, JAMA.

[5]  J. Kersnik,et al.  Attitudes of Slovene general practitioners towards generic drug prescribing and comparison with international studies , 2006, Journal of clinical pharmacy and therapeutics.

[6]  Susan L Ettner,et al.  The implications of choice: prescribing generic or preferred pharmaceuticals improves medication adherence for chronic conditions. , 2006, Archives of internal medicine.

[7]  J. Douketis,et al.  Are brand-name and generic warfarin interchangeable? A survey of Ontario patients and physicians. , 2005, The Canadian journal of clinical pharmacology = Journal canadien de pharmacologie clinique.

[8]  W. Bearden,et al.  Generic Drugs: Consumer, Pharmacist and Physician Perceptions of the Issues , 1980 .

[9]  William H Shrank,et al.  Patients' perceptions of generic medications. , 2009, Health affairs.

[10]  R. Gross,et al.  Generic substitution in the treatment of epilepsy: Patient and physician perceptions , 2008, Epilepsy & Behavior.

[11]  M. Gossell-Williams Generic substitutions: a 2005 survey of the acceptance and perceptions of physicians in Jamaica. , 2007, The West Indian medical journal.

[12]  B. Banahan,et al.  A physician survey on generic drugs and substitution of critical dose medications. , 1997, Archives of internal medicine.

[13]  J. Avorn,et al.  Economic implications of evidence-based prescribing for hypertension: can better care cost less? , 2004, JAMA.

[14]  M Alan Brookhart,et al.  Clinical equivalence of generic and brand-name drugs used in cardiovascular disease: a systematic review and meta-analysis. , 2008, JAMA.

[15]  Kathryn A Phillips,et al.  Potential Savings from Substituting Generic Drugs for Brand-Name Drugs: Medical Expenditure Panel Survey, 19972000 , 2005, Annals of Internal Medicine.

[16]  G. Alexander,et al.  1 CHARACTERISTICS OF PATIENTS RECEIVING PHARMACEUTICAL SAMPLES AND ASSOCIATION BETWEEN SAMPLE RECEIPT AND OUT-OF-POCKET PRESCRIPTION COSTS. , 2007, Journal of Investigative Medicine.

[17]  W. Shrank,et al.  Increasing Generic Drug Use in Medicare Part D: The Role of Government , 2007, Journal of the American Geriatrics Society.

[18]  Rationale and design of the Study Assessing the Effect of Cardiovascular Medications Provided as Low-cost, Evidence-based Generic Samples (SAMPLES) trial. , 2009, American heart journal.

[19]  Lawrence X. Yu,et al.  Comparing Generic and Innovator Drugs: A Review of 12 Years of Bioequivalence Data from the United States Food and Drug Administration , 2009, The Annals of pharmacotherapy.

[20]  A. Awaisu,et al.  Physicians' Views on Generic Medicines: A Narrative Review , 2010 .

[21]  Richard L Kravitz,et al.  Physician communication about the cost and acquisition of newly prescribed medications. , 2006, The American journal of managed care.

[22]  Barbara M Rothenberg,et al.  Impact of alternative interventions on changes in generic dispensing rates. , 2006, Health services research.

[23]  J. Kyriopoulos,et al.  Generic medicines: Greek physicians’ perceptions and prescribing practices , 2009, Journal of clinical pharmacy and therapeutics.